Cytosorbents (CTSO) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
CytoSorbents (CTSO) PT Raised to $16.50 at B.Riley/FBR
August 3, 2018 9:20 AM EDTB.Riley/FBR raised its price target on CytoSorbents (NASDAQ: CTSO) to $16.50 (from $13.00) while maintaining a Buy rating.
... MoreCytoSorbents (CTSO) PT Raised to $18 at Maxim Group
August 3, 2018 7:36 AM EDTMaxim Group raised its price target on CytoSorbents (NASDAQ: CTSO) to $18.00 (from $13.00) while maintaining a Buy rating.
Analsyt Jason McCarthy commented:
Cytosorbents reported another quarter of growth with Cytosorb revenues of $5.24M, up sequentially from $4.4Mthe 24th consecutive quarter of y/y... MoreCytoSorbents (CTSO) PT Raised to $15 at Cowen
August 3, 2018 6:42 AM EDTCowen raised its price target on CytoSorbents (NASDAQ: CTSO) to $15.00 (from $13.00) while maintaining an Outperform rating.
Analyst Josuah Jennings commented, "CTSO again delivered impressive quarterly revenue growth, with product sales of $5.2M, up 72% from last year. Lead product CytoSorb has numerous tailwinds in 2018, including (1) favorable German... More
